Grifols SA $ 14.90 0 (0%)
Warning! GuruFocus has detected 3 Severe warning signs with GIKLY. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Grifols SA () from 2008 to Jan 17 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Grifols stock (GIKLY) PE ratio as of Jan 17 2021 is 24.13. More Details
Grifols PE Ratio (TTM) Historical Data
View and export this data going back to 2008. Start your Free Trial
Grifols PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NYSE:JNJ XSWX:ROG NYSE:PFE XSWX:NOVN NYSE:MRK NYSE:ABBV NYSE:LLY LSE:AZN NYSE:BMY NAS:AMGN XPAR:SAN LSE:GSK NAS:GILD TSE:4519 FRA:A60 NYSE:AGN XTER:BAYN SHSE:600276 TSE:4568 NAS:BIIB
Address Avinguda de la Generalitat, 152-158, Parque empresarial Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 78% of sales in 2019. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics is now roughly 14% of revenue following the Novartis and Hologic deals.